ArticleThe Journal of clinical and aesthetic dermatology2025
Regression Rate of Basal Cell Carcinoma in a Veteran Population: A Study of 317 Cases at the Kansas City Veterans Affairs Medical Center.
Article in The Journal of clinical and aesthetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to assess the regression rate of basal cell carcinoma (BCC) in excision specimens following diagnostic biopsies obtained from patients in a veterans affairs facility.
methodsA retrospective review of biopsy-proven BCC excision cases was conducted. All included biopsy and corresponding excision reports were reviewed to determine the margin status of specimens. Proportion of residual carcinoma cases and regression rate of the tumor were determined.
resultsRegression rate of BCC was estimated to be 47%. The most prevalent subtype was nodular BCC (46%), and the most prevalent location was the head. Tumors located on the trunk and upper extremities were more likely to regress, and those on the head were less likely to regress ( LIMITATIONS: The limitation of our study is that the data may not be generalizable due to our unique study population.
conclusionBCC is a tumor with the potential to regress. However, definitive management resides in complete surgical excision, which will most likely remain the mainstay of treatment in the near future.
Indexed as
Identifiers
41416025PMC12710995What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.